Biotech catalysts

Public drugmakers ranked by their active Phase 3 clinical pipeline, from ClinicalTrials.gov, alongside recent FDA drug recalls from openFDA. A large or growing late-stage pipeline is a forward catalyst; a recent Class I/II recall is a risk flag. 1 of these are also names the PriorMoves 13F model ranks. As of 2026-07-17.

Descriptive context, not a recommendation and not a return claim.

#	Company	Active Phase 3	Recent recalls	Worst class	On model board
1	MRK Merck	141	2	Class II	○
2	LLY Eli Lilly	107	-	-	○
3	JNJ Johnson & Johnson	99	-	-	○
4	PFE Pfizer	91	-	-	○
5	BMY Bristol Myers Squibb	81	-	-	○
6	ABBV AbbVie	77	1	Class III	● 73
7	AMGN Amgen	56	5	Class II	○
8	REGN Regeneron	50	-	-	○
9	GILD Gilead Sciences	39	-	-	○
10	BIIB Biogen	19	-	-	○
11	ALNY Alnylam	0	-	-	○
12	AZN AstraZeneca	0	-	-	○
13	BAX Baxter	0	1	Class II	○
14	BMRN BioMarin	0	-	-	○
15	BNTX BioNTech	0	-	-	○
16	EXEL Exelixis	0	-	-	○
17	GSK GSK	0	-	-	○
18	HIK Hikma	0	1	Class II	○
19	INCY Incyte	0	-	-	○
20	JAZZ Jazz	0	-	-	○
21	MRNA Moderna	0	-	-	○
22	NVAX Novavax	0	-	-	○
23	NVS Novartis	0	1	Class III	○
24	SNY Sanofi	0	-	-	○
25	SRPT Sarepta	0	-	-	○
26	TEVA Teva	0	15	Class II	○
27	VRTX Vertex	0	-	-	○
28	VTRS Viatris	0	2	Class II	○